These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11585158)

  • 1. A cost-effectiveness approach to drug subsidy and pricing in Australia.
    Birkett DJ; Mitchell AS; McManus P
    Health Aff (Millwood); 2001; 20(3):104-14. PubMed ID: 11585158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The subsidy of pharmaceuticals in Australia: processes and challenges.
    Sansom L
    Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceuticals in Australia: priorities in a teaching hospital.
    Kearney BJ
    Physician Exec; 1993; 19(5):63-7. PubMed ID: 10130953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailoring access to high cost, genetically targeted drugs.
    Hall WD; Ward R; Liauw WS; Lu CY; Brien JA
    Med J Aust; 2005 Jun; 182(12):607-8. PubMed ID: 15963014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Australia's 'free-ride' in pharmaceuticals: can it last?
    Kemp R
    Aust Health Rev; 1996; 19(1):81-94. PubMed ID: 10157539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health resource allocation. A made-in-Canada description.
    Noseworthy T
    J Leg Med; 2011 Jan; 32(1):11-26. PubMed ID: 21391053
    [No Abstract]   [Full Text] [Related]  

  • 9. National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities.
    Yoongthong W; Hu S; Whitty JA; Wibulpolprasert S; Sukantho K; Thienthawee W; Han H; Scuffham PA
    Value Health; 2012; 15(1 Suppl):S126-31. PubMed ID: 22265059
    [No Abstract]   [Full Text] [Related]  

  • 10. Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System.
    Yoo SL; Kim DJ; Lee SM; Kang WG; Kim SY; Lee JH; Suh DC
    Int J Environ Res Public Health; 2019 Jan; 16(2):. PubMed ID: 30669602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More of the same is not enough.
    Willison DJ
    Healthc Pap; 2002; 3(1):47-55; discussion 87-94. PubMed ID: 12811111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
    Thatte U; Hussain S; de Rosas-Valera M; Malik MA
    Value Health; 2009; 12 Suppl 3():S18-25. PubMed ID: 20586975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency?
    Viney R
    Aust Health Rev; 2001; 24(2):21-4. PubMed ID: 11496466
    [No Abstract]   [Full Text] [Related]  

  • 17. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health, nursing and midwifery landscapes in Australia.
    Kearney G
    Aust Nurs J; 2010 Apr; 17(9):1. PubMed ID: 20449958
    [No Abstract]   [Full Text] [Related]  

  • 20. The Use of Economic Evidence to Inform Drug Pricing Decisions in Jordan.
    Hammad EA
    Value Health; 2016; 19(2):233-8. PubMed ID: 27021758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.